Skip to main content
Premium Trial:

Request an Annual Quote

Searching for the Origin

An article in the New York Times discusses cancers of unknown primary origins and recently developed genetic tests that may identify where in the body those mystery tumors are coming from -- not knowing the original tissue hampers treatment since many cancer therapies are tailored to combat one sort of cancer. Four genetic tests are trying to help identify the origin of these cancers -- Pathwork Diagnostics' Tissue of Origin test, BioTheranostics' CancerType ID, Agendia's CupPrint, and Rosetta Genomics' MiRview Mets test -- but with mixed results. A recent study showed Agendia's test could accurately classify 83 percent of known samples but only 64 percent of unknown ones. "We try to ask ourselves, 'Is this information going to change the treatment we recommend for the patient?'" MD Anderson's James Abbruzzese says.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.